US Pharmaceutical Market Overview – Healthcare reform, economic pressures and the patent cliff set to impact Pharma

Introduction

The US prescription pharmaceutical market was valued at $279 billion in 2009, with an annual growth rate of 5.5% between 2008 and 2009, having grown at a compound annual growth rate of 5.0% between 2005 and 2009. However, future sales growth will be shaped by three key events: the US recession, healthcare reform and the patent cliff.
Scope

* Overview of US socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property position
* Assesses the size of the US pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
* Examines the US generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
* Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis

Highlights

The once recession-proof industry is now feeling the impact of the economic downturn. As a result of rising unemployment and the number of uninsured, individuals now face difficult healthcare decisions. Action taken by the US government as part of the reform package to offset the growing healthcare burden will also impact Pharma.

US healthcare reform is set to improve coverage but this will be at the expense of containing healthcare costs. Although the pharma industry will benefit from the rise in insured individuals, measures such as the increased Medicaid drug rebate and Medicare donut hole discount will have an immediate negative impact on revenues out to 2014.

As a result of the patent cliff beginning in 2011, Pharma is set to lose $42 billion in US branded sales from drugs facing patent expiry between 2011 and 2012. Consequently, US sales for the top 50 pharma companies are forecast to decline by an average of 2.2% year-on-year between 2010 and 2015.
Reasons to Purchase

* Evaluate the evolving regulatory landscape and the US healthcare reform is set to impact Pharma out to 2019
* Quantify the size and growth of the prescription pharmaceutical market in the US, analyzing key therapy areas, brands and companies
* Assess drivers and resistors of generic and biosimilars uptake in the US as well as the level of erosion brands can expect to face post patent expiry
[Studien Infos ausblenden]

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2

1. US – Executive Summary 3
Strategic scoping and focus 3
Key findings – healthcare drivers and resistors 4
Related reports 22
Upcoming related reports 22

2. US – Socio-demographic and economic analysis 25
US – Key findings 25
US – Demographic trends 27
US – Disease burden 33
US – Political climate 37
US – Economic climate 39
US – Business environment 47

3. US – Healthcare system and drug regulatory analysis 50
US – Key findings 50
US – Healthcare system 53
US – Regulatory issues 71
US – Intellectual property environment 92
US – Pricing and reimbursement 97
US – Health reform is changing the country’s healthcare landscape 114

4. US – Prescription pharmaceutical sales analysis 138
US – Key findings 138
US – Pharmaceutical market size 140
US – Leading therapy areas 142
US – Leading pharmaceutical brands 147
US – Leading pharmaceutical companies 151

5. US – Drug expiry analysis 158
US – Key findings 158
US – Generics market dynamics 161
US – Generics drivers and resistors 165
US – Key generics players 177
US – Small molecule brand erosion 182
US – Biosimilars market dynamics 191

6. US – Pharmaceutical Industry Infrastructure analysis 200
US – Key findings 200
US – Pharmaceutical industry infrastructure overview 201
US – Key company infrastructure 207

7. Bibliography 267
US – Executive summary 267
US – Socio-demographic and economic analysis 268
US – Healthcare systems and regulations 275
US – Prescription pharmaceutical sales 288
US – Drug expiry analysis 289
US – Pharmaceutical industry infrastructure analysis 295

APPENDIX 304
Exchange rates used in this report 304
US brand erosion – additional data and analysis 305
Brand erosion – methodology 307
Datamonitor prescription pharmaceutical definition and therapy area classification 310
About Datamonitor 311
Disclaimer 312
Disclaimer 313
[Inhaltsverzeichnis ausblenden]